key: cord-0016080-ied6hyf9
authors: Svedbom, Axel; Mallbris, Lotus; Ståhle, Mona
title: Risk of respiratory infection in patients with plaque psoriasis
date: 2021-01-10
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2020.12.083
sha: 0787733c5520b8f4fff5d95f1bc63dce1d9f43e8
doc_id: 16080
cord_uid: ied6hyf9

nan

To the Editor: Understanding the risk of respiratory infection in psoriasis and the impact of immunosuppressive treatment is important to inform preventive measures for COVID-19. Therefore, we report data on respiratory infection in patients with psoriasis from a study linking an inception cohort 1 to population-based health care registers on outpatient care, inpatient care (The National Patient Register 2 ), and prescriptions (The Prescribed Drug Register 3 ).

The Stockholm Psoriasis Cohort enrolled patients with new-onset psoriasis and population controls, predominately in Stockholm, Sweden, between 2001 and 2005. 1 The study had ethics approval, and participants provided informed consent (Appendix 1 for information on the study; available at https:// data.mendeley.com/datasets/vh2k3nvsn9/1).

For the analyses at hand, the exposures were mild and moderate-to-severe plaque psoriasis. In a separate analysis, immunosuppressive treatment for psoriasis as observed in the Prescribed Drug Register was a time-dependent exposure. The outcomes in the study were the first respiratory infection after onset from the National Patient Register; and prescriptions of antibiotics and antivirals used to treat respiratory infection from the Prescribed Drug Register (see Supplementary Patients with mild and moderate-to-severe psoriasis were compared with controls. Cox Proportional Hazard models 4 were used to compare time to first diagnosis, and negative binomial regression models 5 were used to compare the incidence of prescriptions between groups. We also compared the incidence of prescriptions of antibiotics and antivirals for respiratory infections when patients were treated with immunosuppressive treatment compared with when they were not. In total, 339 patients with mild plaque psoriasis, 187 patients with moderate-to-severe plaque psoriasis, and 835 controls were included. Among the 526 patients, 121 were treated with immunosuppressants. Baseline characteristics are presented in Table I .

The cumulative incidence of respiratory infection is presented in Fig 1. Follow-up and incidence are presented Supplementary Table 4 (Table S3. 1; available at https://data.mendeley.com/datasets/ vh2k3nvsn9/1). In multivariable analyses psoriasis was associated with increased risk of inpatient or specialist outpatient diagnosed respiratory infection: hazard ratios of 2.0 (95%confidence interval [CI], 1.1-3.6) for patients with mild disease; and 2.5 (95% CI, 1.3-4.9) for patients with moderate-to-severe disease. In multivariable analysis of prescriptions, mild disease was associated with an incidence rate ratio of 1.3 (95% CI, 1.1-1.5) and moderate-to-severe disease with an incidence rate ratio of 1.5 (95% CI, 1.2-1.9).

The 121 patients treated with immunosuppressants were on average exposed to immunosuppressants for 3.1 years and unexposed to immunosuppressants for 5.4 years. The incidence of infection per person-year on and off immunosuppressive treatment was estimated at 0.31 and 0.29, respectively (P ¼ .31).

Psoriasis is associated with increased risk of respiratory infection independently of known risk factors for infection, with moderate-to-severe psoriasis conferring higher risk than mild psoriasis. Immunosuppressive treatment did not further increase the risk for respiratory infection. These findings can inform risk mitigation strategies and preventive efforts for patients with psoriasis during the COVID-19 pandemic. Limitations include data on infections not coming to clinical attention and generalizability. 

Psoriasis phenotype at disease onset: clinical characterization of 400 adult cases

External review and validation of the Swedish national inpatient register

The new Swedish Prescribed Drug Register-opportunities for pharmacoepidemiological research and experience from the first six months

Regression models and life tables

Negative binomial and mixed Poisson regression

Axel Svedbom is an employee of ICON plc, a contract research organization. Lotus Mallbris is an employee of Eli Lilly and Company. Mona St ahle has received honoraria for serving as an advisor and for participating in symposia arranged by Abbvie, Novartis, Pfizer, Eli Lilly, Janssen-Cilag, and Leo Pharma.